Evidence map›Paper›PMID 33219121›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A.

Se-Jin Lee, Adam Lehar, Yewei Liu, Chi Hai Ly, Quynh-Mai Pham, Michael Michaud, Renata Rydzik, Daniel W Youngstrom, Michael M Shen, Vesa Kaartinen and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Se-Jin LeeThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032; sejlee@uchc.edu.
Adam LeharThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032.
Yewei LiuThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032.
Chi Hai LyPaul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA 94305.
Quynh-Mai PhamThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032.ORCID 0000-0002-9479-9604
Michael MichaudThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032.
Renata RydzikDepartment of Orthopaedic Surgery, University of Connecticut School of Medicine, Farmington, CT 06030.
Daniel W YoungstromDepartment of Orthopaedic Surgery, University of Connecticut School of Medicine, Farmington, CT 06030.ORCID 0000-0002-1193-8868
Michael M ShenDepartment of Genetics and Development, Columbia University, New York, NY 10032.ORCID 0000-0002-4042-1657
Vesa KaartinenDepartment of Biologic and Materials Sciences and Prosthodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109.ORCID 0000-0002-9432-510X
Emily L Germain-LeeDepartment of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030.ORCID 0000-0002-5727-610X
Thomas A RandoPaul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA 94305.
Jackson Laboratory · USUniversity of Connecticut · USColumbia University · USStanford University · USUniversity of Michigan · USVA Palo Alto Health Care System · US

Funding

Wnt signaling in muscle stem cell agingP01AG036695 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI THOMAS A. RANDO · 2011 to 2026
$29.3M
Characterization of Myostatin and GDF-11R01AR060636 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LEE, SE-JIN · 2010 to 2020
$3.7M
Molecular Regulation of Stem Cell QuiescenceR01AR073248 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RANDO, THOMAS A. · 2018 to 2022
$2.6M
TGF-beta family members and their binding proteins in aging skeletal muscleR01AG052962 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LEE, SE-JIN, RANDO, THOMAS A. · 2017 to 2020
$1.9M
NIAMS NIH HHS R01 AR060636NIAMS NIH HHS R01 AR073248NIA NIH HHS P01 AG036695NIA NIH HHS R01 AG052962
6 · The paper itself

Abstract

Myostatin (MSTN) is a transforming growth factor-β (TGF-β) family member that normally acts to limit muscle growth. The function of MSTN is partially redundant with that of another TGF-β family member, activin A. MSTN and activin A are capable of signaling through a complex of type II and type I receptors. Here, we investigated the roles of two type II receptors (ACVR2 and ACVR2B) and two type I receptors (ALK4 and ALK5) in the regulation of muscle mass by these ligands by genetically targeting these receptors either alone or in combination specifically in myofibers in mice. We show that targeting signaling in myofibers is sufficient to cause significant increases in muscle mass, showing that myofibers are the direct target for signaling by these ligands in the regulation of muscle growth. Moreover, we show that there is functional redundancy between the two type II receptors as well as between the two type I receptors and that all four type II/type I receptor combinations are utilized in vivo. Targeting signaling specifically in myofibers also led to reductions in overall body fat content and improved glucose metabolism in mice fed either regular chow or a high-fat diet, demonstrating that these metabolic effects are the result of enhanced muscling. We observed no effect, however, on either bone density or muscle regeneration in mice in which signaling was targeted in myofibers. The latter finding implies that MSTN likely signals to other cells, such as satellite cells, in addition to myofibers to regulate muscle homeostasis.

Indexed as

Muscle DevelopmentActivin Receptors, Type IActivin Receptors, Type IIActivinsAnimalsMice, Inbred C57BLMuscle Fibers, SkeletalMusclesMyostatinOrgan Sizeactivin AActivin Receptors, Type IActivin Receptors, Type IIActivinsMyostatinactivinmyostatinreceptorsskeletal muscle

Identifiers

PMID33219121
PMCPMC7733802
OpenAlexW3106391536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.